<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00382330</url>
  </required_header>
  <id_info>
    <org_study_id>0120050348</org_study_id>
    <nct_id>NCT00382330</nct_id>
  </id_info>
  <brief_title>Chemoprevention of Cancer in the Lower Female Genital Tract: The Antineoplastic Activity of the Fungicide Ciclopirox.</brief_title>
  <official_title>Chemoprevention of Cancer in the Lower Female Genital Tract: The Antineoplastic Activity of the Fungicide Ciclopirox.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Medicine and Dentistry of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if regular and daily repeated application of the
      ciclopirox lotion to vulva will make the precancerous lesion(s) shrink or even disappear.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Vulvar Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclopirox</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between the ages 18 and 75 years.

          -  Patients may be carriers of the Human Immunodeficiency Virus (HIV).

          -  Patients must have been diagnosed with precancerous lesion(s) of the vulva by tissue
             sampling (biopsy-proven vulvar intraepithelial neoplasia grade II or III)

          -  Patients must be able to come to University Hospital for their initial appointment in
             Gynecologic Oncology Clinic, and for the eight follow-up visits in that Clinic
             required by the protocol.

        Exclusion Criteria:

          -  Pregnant or patients who are breast feeding a baby.

          -  Patients who have been diagnosed with a vaginal yeast infection.

          -  Patients who have undergone prior surgery for precancerous lesion(s) of the vulva.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Bernadette Cracchiolo, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Medicine and Dentistry of New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Medicine and Dentistry of NJ</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2006</study_first_submitted>
  <study_first_submitted_qc>September 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2006</study_first_posted>
  <last_update_submitted>September 5, 2013</last_update_submitted>
  <last_update_submitted_qc>September 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vulva</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vulvar Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antineoplastic Agents</mesh_term>
    <mesh_term>Ciclopirox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

